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Abstract
Background:  Only few studies have assessed the relative impact of prenatal and postnatal
exposure to tobacco smoke on the child's later asthma or chronic respiratory symptoms and to
our knowledge no studies have elaborated respiratory infections and allergies in this context.
Objective:  To assess the effects of prenatal and postnatal exposure to tobacco smoke on
respiratory health of Russian school children.
Methods: We studied a population of 5951 children (8 to12 years old) from 9 Russian cities,
whose parents answered a questionnaire on their children's respiratory health, home environment,
and housing characteristics. The main health outcomes were asthma, allergies, chronic respiratory
symptoms, chronic bronchitis, and upper respiratory infections. We used adjusted odds ratios
(ORs) from logistic regression analyses as measures of effect.
Results: Prenatal exposure due to maternal smoking had the strongest effects on asthma (adjusted
OR 2.46, 95% CI 1.19–5.08), chronic bronchitis (adjusted OR 1.45, 95% CI 1.08–1.96) and
respiratory symptoms, such as wheezing (adjusted OR 1.30, 95% CI 0.90–1.89). The associations
were weaker for exposure during early-life (adjusted ORs 1.38/1.27/1.15 respectively) and after 2
years of age (adjusted ORs 1.45/1.34/1.18) compared to prenatal exposure and the weakest or
non-existent for current exposure (adjusted ORs 1.05/1.09/1.06). Upper respiratory infections
were associated more strongly with early-life exposure (adjusted OR 1.25, 95% CI 1.09–1.42) than
with prenatal (adjusted OR 0.74, 95% CI 0.54–1.01) or current exposure (adjusted OR1.05, 95%
CI 0.92–1.20). The risk of allergies was also related to early life exposure to tobacco smoke
(adjusted OR 1.26, 95% CI 1.13–1.42).
Conclusion:  Adverse effects of tobacco smoke on asthma, chronic bronchitis, and chronic
respiratory symptoms are strongest when smoking takes place during pregnancy. The relations are
weaker for exposure during early-life and after 2 years of age and weakest or non-existent for
current exposure.
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Background
There is strong evidence that maternal smoking during
pregnancy is harmful to fetal development. Tobacco
smoke constituents pass placenta and reduce intrauterine
fetal growth and increases the risk of preterm delivery [1].
There is also accumulating evidence that maternal smok-
ing in pregnancy may influence the fetal development of
respiratory system, suggested by findings of a relation
between maternal smoking in pregnancy and lung func-
tion impairment in newborns [2-7]. Based on a recent
review, there is strong evidence that exposure to environ-
mental tobacco smoke (ETS) in childhood causes chronic
respiratory symptoms, such as cough, phlegm, and wheez-
ing, susceptibility to lower respiratory infections and to
acute and recurrent otitis media, and that it has a causal
role in childhood asthma [8]. Evidence of the effects of
ETS exposure on allergies is inconsistent [8]. There is also
evidence that maternal smoking in pregnancy increase the
risk of asthma [8-11] and wheezing [11,12] in childhood.
Only few studies have assessed the relative impact of pre-
natal and postnatal exposure to tobacco smoke on the
child's later asthma or chronic respiratory symptoms
[10,12], and to our knowledge no studies have elaborated
respiratory infections and allergies in this context.
We assessed the independent and joint effects of prenatal
and postnatal exposure to tobacco smoke on the risk of
asthma and other respiratory problems at school age in a
study of Russian school children in 9 cities. We also elab-
orated whether the effect of smoking in pregnancy on res-
piratory problems is mainly mediated through reduced
fetal growth and duration of pregnancy.
Methods
Study design and population
We conducted a cross-sectional study, which was designed
to assess the effects of air pollution on children's respira-
tory health. The study population was recruited through
primary schools located in the vicinity of air pollution
monitoring stations in 12 areas in 9 Russian cities in the
Middle Urals and Upper Volga regions [13]. One school
from each area was selected. The study population com-
prised 5951 2–5th graders aged 8 to 12 years. The response
rate in schools varied from 96% to 98%. The question-
naire, modified from previous European and North Amer-
ican questionnaires for the Russian conditions [14-16],
inquired about the child's personal characteristics, health
information, and socioeconomic factors. Local elemen-
tary school teachers were trained to instruct the parents
about filling out the questionnaires, and parents and
guardians were invited to meetings after the school day.
After signing an informed consent, a parent completed the
questionnaire.
Health outcomes
The main health outcomes were asthma (ever, current),
allergies (any, respiratory), chronic respiratory symptoms
(wheezing, cough, phlegm), chronic bronchitis (doctor
diagnosed ever, current) and upper respiratory infections
(any, severe). In addition we constructed a composite var-
iable called "asthma-like symptoms". These are defined in
detail in Table 1.
Exposure assessment
Exposure assessment was based on questionnaire infor-
mation on maternal smoking during pregnancy (prenatal
exposure), exposure to tobacco smoke during the first two
years of life (early-life exposure), after the age of 2, and at
the time of the survey (current exposure). Table 2 shows
the definitions of the exposure parameters and the preva-
lences of exposure in the study population.
Statistical methods
We estimated the prevalences (%) of the respiratory out-
comes and exposure with 95 % confidence intervals based
on the binomial distribution. Odds ratio was the measure
of effect. We used logistic regression analysis to estimate
adjusted odds ratios for the relations between exposure to
tobacco smoke, and pregnancy and respiratory outcomes.
The basic adjustment was made using the following core
covariates: study area, age, gender, mother's education
(low, medium, high), and parental asthma. We fitted also
income, furry pets and sharing a bedroom as covariates,
but excluded them if they changed the studied estimates
less than 10%. Additional adjustment was made for low
birth weight and preterm delivery when studying the rela-
tions between maternal smoking and respiratory out-
comes. Maternal smoking was included as an additional
covariate when studying the relations of low birth weight
and preterm delivery to respiratory outcomes.
Results
Study population
Table 3 describes the characteristic of the study popula-
tion according to exposure to tobacco smoke. The age and
sex distributions were similar among the exposed and the
reference group, but the exposed were more likely to have
mother with low education, to be born prematurely, have
lower birth weight, and to be exposed to furry or feathery
pets.
Maternal smoking in pregnancy and the risk of adverse 
pregnancy outcomes
Only 4.3% of the mothers reported having smoked during
pregnancy. Maternal smoking was a determinant of both
preterm delivery and low birth weight. The risk of low
birth weight was higher among newborns of smoking
women compared to those of non-smokers with an
adjusted odds ratio of 1.34 (95% CI 0.82–2.18). The cor-Respiratory Research 2006, 7:48 http://respiratory-research.com/content/7/1/48
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responding effect estimate for preterm delivery was 1.85
(95% CI 1.30–2.68).
Fetal growth, preterm delivery and the risk of respiratory 
outcomes
Both preterm delivery and low birth weight increased the
risk of asthma and asthma-like symptoms, chronic respi-
ratory symptoms, and doctor-diagnosed bronchitis, as
shown in Table 4. The risk of severe upper respiratory
infections was related to preterm delivery (adjusted OR
1.21, 95% CI 0.99–1.48), but not to low birth weight
(adjusted OR 1.01, 95% CI 0.79–1.30). The risk of aller-
gies was not related to preterm delivery, but interestingly
the risk of any allergy was significantly lower among chil-
dren with low birth weight (adjusted OR 0.78, 95% CI
0.61–0.99).
Prenatal and postnatal exposure and the risk of 
respiratory outcomes
Table 5 shows the relations between prenatal, early-life,
after 2 years of age, and current exposures and the risk of
various health outcomes. The effect estimates are dis-
played adjusted for the core covariates and further for pre-
term delivery and low birth weight.
Maternal smoking during pregnancy had a strong consist-
ent effect on the risk of doctor-diagnosed asthma (ever:
adjusted OR 2.46, 95% CI 1.19–5.08), asthma-like symp-
toms (adjusted OR 1.39 95% CI 0.93–2.08), current
wheezing (adjusted OR 1.30, 95% CI 0.90–1.89), cough
(adjusted OR 1.54, 95% CI 1.14–2.08) and doctor diag-
nosed bronchitis (ever: adjusted OR 1.45, 95% CI 1.08–
1.96). The occurrence of phlegm, upper respiratory infec-
Table 1: Prevalence of the respiratory health outcomes in the study population. The 95% confidence intervals are based on binomial 
distribution.
Health outcome Definition Prevalence (95% CI)
Doctor diagnosed asthma
Ever Ever told by doctor that the child has asthma 1.9
(1.5 – 2.3)
Current Diagnosed by doctor with shortness of breath, wheeze, or use of asthma 
medication within past 12 months
1.5
(1.2 – 1.8)
Asthma like symptoms Asthma symptoms or asthma medication use, awakening by asthma, wheezing 
upon exercise, or hospital care for wheezing within past 12 months
10.3
(9.5 – 11.1)
Wheezing
Ever without cold Wheezing heard from distance without a cold 3.1
(2.6 – 3.5)
Current Wheezing heard from distance with or without a cold, shortness of breath with 
wheezing, awakening at night by wheezing, wheezing with exercise, or use of 
medication or hospitalisation within past 12 months for wheezing
13.4
(12.5 – 14.3)
Cough
Any ever Usual cough day or night 25.7
(24.6 – 26.9)
Any persistent Cough ≥ 3 consecutive months within past 12 months 5.5
(4.9 – 6.1)
Phlegm
Ever Wet cough or phlegm produced without a cold 7.0
(6.3 – 7.7)
Persistent Wet cough or phlegm ≥ 3 consecutive months within past 12 months 1.5
(1.2 – 1.9)
Doctor diagnosed bronchitis ever Ever told by doctor that child has bronchitis 25.6
(24.5 – 26.8)
Current bronchitis Doctor-diagnosed bronchitis within past 12 months 8.3
(7.6 – 9.0)
Respiratory infections
Upper respiratory infection Acute upper respiratory infection within past 12 months 76.9
(75.8 – 78.0)
Severe upper respiratory infection Two or more acute upper respiratory infections within past 12 months 24.2
(23.1 – 25.3)
Allergy
Any Doctor-diagnosed allergy, reported hay fever, or pollenosis 33.2
(32.0 – 34.4)
Respiratory Hay fever or doctor-diagnosed allergies to airborne substances (e.g., dust, 
animals, molds, pollens, air pollution, tobacco smoke)
8.0
(7.3 – 8.7)Respiratory Research 2006, 7:48 http://respiratory-research.com/content/7/1/48
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tions and allergy were not related to maternal smoking in
pregnancy.
The effect estimates of early-life exposure for asthma and
asthma like symptoms were lower than corresponding
estimates for maternal smoking in pregnancy, varying
from 1.04 to 1.38. The effect estimates of current asthma
(adjusted OR 1.35, 95% CI 0.86–2.15), asthma ever
(adjusted OR 1.38, 95% CI 0.93–2.06) and current
wheezing (adjusted OR 1.15, 95% CI 1.01–1.38) were ele-
vated, although not reaching statistical significance. That
of asthma-like symptoms (adjusted OR 1.26, 95% CI
1.05–1.51) was statistically significant. Adjustment for
preterm delivery and low birth weight did not alter the
effect estimates. The risk of cough (ever: adjusted OR 1.34,
95% CI 1.18–1.52), doctor diagnosed bronchitis
(adjusted OR 1.27, 95% CI 1.12–1.44), upper respiratory
infections (adjusted OR 1.25, 95% CI 1.09–1.42) as well
as allergies (any: adjusted OR 1.26, 95% CI 1.13–1.42;
respiratory: adjusted OR 1.20, 95% CI 0.99–1.47) were
also related to early-life exposure to ETS. The effect esti-
mates for exposure after 2 years of age were similar to
those of early-life exposure.
The risk of asthma, asthma like symptoms, wheezing, and
upper respiratory infections were not related to current
exposure to ETS, but the effect estimates for cough (any
adjusted OR 1.33, 95% CI 1.17–1.51) and doctor diag-
nosed bronchitis (adjusted OR 1.09, 95% CI 0.96–1.24)
as well as any allergy (adjusted OR 1.11, 95% CI 0.99–
1.25) were elevated.
Table 6 compares the effects of prenatal exposure only,
postnatal exposure only and both prenatal and postnatal
exposure. In general the effect of experiencing both prena-
tal and postnatal exposure was stronger than the effect of
postnatal exposure only. There were only 10 individuals
who were exposed only during pregnancy and therefore
the estimates are either not available or with wide confi-
dence intervals. Therefore the comparison of independent
effects of prenatal and postnatal exposures was possible
for only few outcomes. The effects of prenatal exposure
appeared to be stronger for asthma like symptoms and
bronchitis.
Discussion
Our population-based epidemiologic study in nine Rus-
sian cities shows the harmful effects of fetal and early-life
exposure to tobacco smoke products. Prenatal exposure
due to maternal smoking had the strongest effects on
asthma, chronic bronchitis and respiratory symptoms.
The associations were weaker for exposure during early-
life and after 2 years of age and weakest or non-existent for
current exposure. Upper respiratory infections were asso-
ciated more strongly with early-life exposure than with
prenatal exposure. The risk of allergies was also weakly
related to both prenatal and postnatal exposure to
tobacco smoke.
Table 2: Exposure to tobacco smoke in Russian school children (N = 5971).
Exposure Definition Prevalence (95% CI)
Fetal exposure: Mother smoked 
during pregnancy
Did this child's mother smoke while she was pregnant with this child? If yes: (A) 
Specify in figures number of cigarettes per week if she was an occasional smoker. 
(B) Specify in figures number of cigarettes per day if she smoked every day.
4.3
(3.8 – 4.9)
Early-life exposure: ETS when child 
was younger that 2 years
Between the times this child was born and he or she turned 2 years old, were 
there any smokers in regular contact with the child? Include regular visitors, for 
example, grandparents or baby-sitters. If yes: Did this child's mother (or 
stepmother or other female taking care of the child) smoke during this period?
46.5
(45.2 – 47.7)
ETS when child after 2 years of age Between the times the child turned 2 years old and he or she started school, were 
there any smokers in regular contact with the child? Include regular visitors, for 
example, grandparents or baby-sitters. If yes: Did this child's mother (or 
stepmother or other female taking care of the child) smoke during this period?
51.1
(49.8 – 52.4)
Current smokers in the household Does anyone daily smoke cigarettes, papirosy (Russian non-filter cigarette), cigars, 
or pipes in this child's home? If yes: (A) On average, how many cigarettes or 
papirosy, in total, are smoked in the home each day when the child is at home? (B) 
On average, how many cigars are smoked in the home each day while the child is 
at home? (C) On average, how many pipes are smoked in the home each day while 
the child is at home?
46.1
(44.9 – 47.4)
Prenatal exposure only 0.2
(0.1 – 0.3)
Postnatal exposure only 59.8
(58.6 – 61.1)
Both prenatal and postnatal 
exposure
4.1
(3.6 – 4.7)
Any tobacco smoke exposure Any of the above. 64.5
(63.3 – 65.7)Respiratory Research 2006, 7:48 http://respiratory-research.com/content/7/1/48
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Although maternal smoking was, as expected, a strong
determinant of preterm delivery and low birth weight,
and these adverse pregnancy outcomes were strong pre-
dictors of asthma and other respiratory problems, adjust-
ment for preterm delivery and low birth weight had little
influence on the associations between prenatal tobacco
smoke exposure and respiratory outcomes.
Validity of results
We achieved a very high response rate due to strong sup-
port by the parents and teachers and this practically elim-
inates selection bias related to participation. Information
on exposure to tobacco smoke was collected retrospec-
tively and there is a possibility for both random and sys-
tematic errors. Maternal smoking during pregnancy was
reported to be much lower (4%) compared to maternal
smoking after the delivery (12 %). This could reflect prob-
lems in recall or cultural behavior to quit smoking during
pregnancy. The latter alternative is supported by our sim-
ilar findings in another Russian female population in
Karelia, North-West Russia (J Jaakkola, unpublished
observation), where smoking during pregnancy was 5%
whereas the smoking was 25% when the child was at
school. Observed associations between maternal smoking
and low birth weight, which are consistent with previ-
ously published meta-analyses [1] and research reports
[9], support the validity of information on prenatal expo-
sure indirectly. Given the nature of the study design we
can not fully exclude the possibility of non-comparable
exposure information from parents of ill and healthy chil-
dren. We were able to adjust the effect estimates for several
potential confounders.
Synthesis with previous knowledge
Only few previous studies have elaborated the relative
contributions of prenatal and postnatal exposures to ETS
on asthma [10,11], and chronic respiratory symptoms
[11,12], and to our knowledge no studies have focused on
respiratory infections or allergies.
Our findings on the stronger effect of prenatal exposure
on asthma and wheezing compared with postnatal expo-
sure are consistent with the results of a cross-sectional
study of 11,500 8 to 11 years old children in 24 US and
Canadian communities [11]. A recent cross-sectional
study of 5 762 Californian school children [10] also pro-
vided evidence of the relative importance of prenatal
exposure in development of asthma with a retrospective
recording of in utero and previous postnatal and current
exposure. In utero exposure to maternal smoking without
subsequent postnatal exposure to ETS was related to the
presence of asthma in 4th, 7th, and 10th grade children with
an adjusted odds ratio of 1.8 (95% CI 1.1 – 2.9). In con-
trast, current or previous postnatal exposure to ETS was
not associated with asthma risk, but the risk of lifetime
wheezing was increased with an odds ratio of 1.3 (95% CI
1.1 – 1.5). Lux and colleagues showed in a longitudinal
study of 8561 English children that maternal smoking
during pregnancy causes wheezing during the first 30
months of life independently from postnatal exposure
[11]. A large population-based cohort study of 55,000
Finnish children estimated a 35% increased risk of asthma
by the age of 7 years related to maternal smoking of over
10 cigarettes per day during pregnancy [9]. Similarly to the
present study, maternal smoking was a strong determi-
Table 3: Characteristics of the study population by exposure to tobacco products, either through maternal smoking in pregnancy or 
environmental tobacco smoke in lifetime.
Characteristic Exposed, N (%) Reference, N (%) Total, N(%)
Total 3790 (64.5) 2084 (35.5) 5874
Age
8 561 (14.8) 317 (15.2) 878 (14.9)
9 1268 (33.5) 675 (32.4) 1943 (33.1)
10 1216 (32.1) 654 (31.4) 1870 (31.8)
11 647 (17.1) 396 (19.0) 1043 (17.8)
12 98 (2.6) 42 (2.0) 140 (2.4)
Gender, boy 1918 (50.6) 1053 (50.5) 2971 (50.6)
Mother's education
Higher 636 (16.9) 492 (23.7) 1128 (19.3)
Incomplete higher or college 2070 (55.0) 1102 (53.2) 3172 (54.4)
Secondary 1056 (28.1) 479 (23.1) 1535 (26.3)
Parental asthma 66 (1.8) 41 (2.0) 107 (1.8)
Low birth weight ( ≤ 2500 g) 248 (6.9) 109 (5.5) 357 (6.4)
Premature birth ( < 37 weeks) 390 (10.5) 172 (8.3) 562 (9.7)
Income below average 2404 (63.9) 1259 (60.8) 3663 (62.8)
Others sleeping in the same room with child 2760 (73.5) 1490 (71.9) 4250 (72.9)
Furry or feathery pets 2421 (65.6) 1247 (61.4) 3668 (64.1)Respiratory Research 2006, 7:48 http://respiratory-research.com/content/7/1/48
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nant of both preterm delivery and low birth weight, and
these adverse pregnancy outcomes were strong predictors
of asthma, but practically none of the effect of maternal
smoking on asthma was mediated via the pregnancy out-
comes.
In the present study prenatal exposure had also a stronger
effect on both lifetime and current chronic bronchitis
compared with early life exposure and there was no asso-
ciation between current exposure and chronic bronchitis.
To our knowledge this has not been reported before.
However, the occurrence of upper respiratory infections
during the previous year was related to early life exposure
to ETS, but not to prenatal or current exposure.
Our results strengthen the evidence that also postnatal
exposure to tobacco smoke increases the risk of asthma in
childhood. The effect estimates for early-life exposure and
exposure after the age of two were consistently elevated
suggesting a 30% increase in risk, although there was no
association between current exposure and asthma. The
latter could be explained by avoidance of smoking in the
presence of the child after the diagnosis of asthma. Unfor-
tunately the number of children with prenatal exposure
only was too small to get good estimates of the independ-
ent effect of prenatal exposure only. However the effect of
both prenatal and postnatal exposure on asthma was
much stronger (adjusted OR 3.48) than the effect of post-
natal exposure only (adjusted OR 1.32), suggesting a syn-
ergistic effect of prenatal and postnatal exposures. There is
evidence that maternal smoking in pregnancy reduces the
fetal development of lung function [2-7], which may play
a role in the susceptibility to the effects of exposure to
environmental tobacco smoke after delivery. Maternal
Table 4: Crude and adjusted odds ratios for respiratory health outcomes according to low birth weight and preterm delivery.
Health outcome Preterm delivery ( < 37 weeks) Low birth weight ( < 2500 g)
Crude OR (95% CI) Adjusted 1 OR (95% CI) Crude OR (95% CI) Adjusted 1 OR (95% CI)
Doctor diagnosed asthma
Ever 1.80
(1.06 – 3.04)
1.96
(1.14 – 3.35)
1.73
(0.92 – 3.27)
1.88
(0.98 – 3.59)
Current 1.83
(1.00 – 3.34)
1.95
(1.06 – 3.62)
1.93
(0.95 – 3.89)
2.05
(0.99 – 4.22)
Asthma like symptoms 1.47
(1.13 – 1.90)
1.48
(1.14 – 1.93)
1.38
(1.00 – 1.90)
1.43
(1.03 – 1.99)
Wheezing
Ever without cold 1.54
(0.99 – 2.40)
1.62
(1.04 – 2.54)
1.67
(1.00 – 2.79)
1.76
(1.04 – 2.96)
Current 1.28
(1.00 – 1.63)
1.30
(1.01 – 1.66)
1.19
(0.88 – 1.62)
1.24
(0.91 – 1.69)
Cough
Ever 1.38
(1.14 – 1.67)
1.38
(1.13 – 1.68)
1.22
(0.96 – 1.56)
1.27
(0.99 – 1.62)
Persistent 1.78
(1.28 – 2.46)
1.86
(1.34 – 2.59)
1.66
(1.12 – 2.48)
1.72
(1.15 – 2.58)
Phlegm
Ever 1.21
(0.87 – 1.68)
1.23
(0.88 – 1.71)
1.15
(0.76 – 1.73)
1.18
(0.78 – 1.78)
Persistent 2.52
(1.47 – 4.34)
2.73
(1.57 – 4.76)
2.13
(1.09 – 4.16)
2.26
(1.14 – 4.47)
Doctor diagnosed bronchitis ever 1.50
(1.24 – 1.81)
1.55
(1.28 – 1.88)
1.53
(1.22 – 1.93)
1.63
(1.29 – 2.06)
Current bronchitis 1.49
(1.12 – 1.97)
1.52
(1.14 – 2.02)
1.28
(0.89 – 1.84)
1.32
(0.91 – 1.92)
Respiratory infections
Upper respiratory infection 1.10
(0.89 – 1.36)
1.11
(0.89 – 1.38)
1.06
(0.81 – 1.38)
1.06
(0.81 – 1.39)
Severe upper respiratory infection 1.22
(1.00 – 1.48)
1.21
(0.99 – 1.48)
1.01
(0.79 – 1.30)
1.01
(0.79 – 1.30)
Allergy
Any 1.01
(0.84 – 1.21)
1.04
(0.86 – 1.26)
0.78
(0.62 – 0.99)
0.78
(0.61 – 0.99)
Respiratory 1.13
(0.83 – 1.55)
1.14
(0.83 – 1.57)
0.93
(0.62 – 1.40)
0.94
(0.62 – 1.41)
1 – Odds ratios adjusted for study area, age, gender, mother's education, parental asthma, maternal smoking during pregnancy.Respiratory Research 2006, 7:48 http://respiratory-research.com/content/7/1/48
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smoking in pregnancy may also have other effects increas-
ing the susceptibility, including effects on development
and maturation of the pulmonary immune system [17]
leading to an increased bronchial reactivity in early child-
hood as shown by Young and colleagues [7].
Early life exposure to ETS was a determinant of both any
and respiratory allergy at school age. There was a weak
non-significant association between prenatal exposure
and respiratory allergy and no association with any
allergy. There was also a weak positive association
between current exposure and risk of any allergy. In their
systematic review based on 36 relevant articles in 1998,
Strachan and Cook [18] concluded that parental smoking,
either before or immediately after birth, is unlikely to
increase the risk of allergic sensitisation in children. In a
Norwegian study, a negative association between prenatal
smoking and childhood atopy was found, but rather than
proposing a causal relation the investigators suggest that
selective avoidance of smoking during pregnancy is an
alternative explanation [19].
Concluding remarks
This large epidemiologic study in Russian children con-
firms that smoking during pregnancy and in the presence
of children is harmful for respiratory health increasing the
risk of asthma, chronic bronchitis, and respiratory infec-
tions and possibly allergies. The results strengthen the evi-
dence that the adverse effects of tobacco smoke on
asthma, chronic bronchitis, and chronic respiratory symp-
toms are strongest when smoking takes place during preg-
nancy and stronger during early life compared with
exposure in school age. Although maternal smoking
reduces duration of gestation and fetal growth and these
pregnancy outcomes predict respiratory illness, little of
the effect of maternal smoking in pregnancy on respira-
tory health is mediated via preterm delivery and low birth
weight. In conclusion, smoking in pregnancy and in the
presence of children is among the most serious preventa-
ble hazards to children's health.
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Table 5: Adjusted odds ratios for respiratory health outcomes according prenatal, early-life and current exposure.
Health outcome Prenatal exposure Early-life exposure Exposure after age of 2 Current exposure
Adjusted OR 
1 (95% CI)
Adjusted OR 
2 (95% CI)
Adjusted OR 
1 (95% CI)
Adjusted OR2 
(95% CI)
Adjusted OR 
1 (95% CI)
Adjusted OR 
2 (95% CI)
Adjusted OR 
1 (95% CI)
Adjusted OR 
2 (95% CI)
Doctor diagnosed asthma
Ever 2.40
(1.17 – 4.93)
2.46
(1.19 – 5.08)
1.39
(0.94 – 2.06)
1.38
(0.93 – 2.06)
1.45
(0.97 – 2.17)
1.45
(0.96 – 2.18)
1.10
(0.74 – 1.63)
1.05
(0.70 – 1.58)
Current 2.55
(1.13 – 5.78)
2.64
(1.16 – 6.03)
1.35
(0.87 – 2.12)
1.36
(0.86 – 2.15)
1.44
(0.91 – 2.27)
1.44
(0.90 – 2.32)
1.19
(0.75 – 1.87)
1.09
(0.68 – 1.74)
Asthma like 
symptoms
1.48
(1.01 – 2.15)
1.39
(0.93 – 2.08)
1.28
(1.07 – 1.52)
1.26
(1.05 – 1.51)
1.23
(1.03 – 1.47)
1.22
(1.02 – 1.47)
1.09
(0.91 – 1.30)
1.09
(0.90 – 1.30)
Wheezing
Ever without cold 0.74
(0.30 – 1.83)
0.59
(0.21 – 1.63)
1.24
(0.91 – 1.69)
1.24
(0.91 – 1.70)
1.40
(1.02 – 1.92)
1.42
(1.03 – 1.96)
1.00
(0.73 – 1.38)
1.00
(0.72 – 1.37)
Current 1.37
(0.97 – 1.94)
1.30
(0.90 – 1.89)
1.18
(1.01 – 1.38)
1.15
(0.98 – 1.36)
1.20
(1.03 – 1.41)
1.18
(1.00 – 1.39)
1.09
(0.93 – 1.28)
1.06
(0.90 – 1.25)
Cough
Ever 1.51
(1.13 – 2.02)
1.54
(1.14 – 2.08)
1.35
(1.2 – 1.53)
1.34
(1.18 – 1.52)
1.49
(1.31 – 1.68)
1.46
(1.28 – 1.66)
1.33
(1.18 – 1.51)
1.33
(1.17 – 1.51)
Persistent 1.11
(0.63 – 1.95)
0.98
(0.53 – 1.8)
1.27
(1.00 – 1.6)
1.20
(0.94 – 1.53)
1.27
(1 – 1.62)
1.23
(0.96 – 1.58)
1.24
(0.98 – 1.58)
1.19
(0.93 – 1.52)
Phlegm
Ever 0.98
(0.58 – 1.65)
0.98
(0.57 – 1.69)
1.15
(0.93 – 1.41)
1.15
(0.92 – 1.42)
1.39
(1.13 – 1.72)
1.38
(1.11 – 1.71)
1.31
(1.06 – 1.62)
1.37
(1.1 – 1.7)
Persistent 0.56
(0.14 – 2.34)
0.56
(0.13 – 2.35)
1.33
(0.85 – 2.07)
1.33
(0.84 – 2.11)
1.68
(1.05 – 2.68)
1.74
(1.07 – 2.84)
0.82
(0.52 – 1.31)
0.84
(0.52 – 1.35)
Doctor-diag 
bronchitis ever
1.41
(1.06 – 1.88)
1.45
(1.08 – 1.96)
1.28
(1.14 – 1.45)
1.27
(1.12 – 1.44)
1.33
(1.18 – 1.51)
1.34
(1.18 – 1.52)
1.12
(0.99 – 1.26)
1.09
(0.96 – 1.24)
Current 
bronchitis
1.71
(1.14 – 2.56)
1.63
(1.06 – 2.49)
1.06
(0.87 – 1.28)
1.04
(0.85 – 1.27)
1.11
(0.92 – 1.34)
1.10
(0.90 – 1.34)
1.01
(0.83 – 1.22)
0.96
(0.79 – 1.18)
Respiratory infections
Upper respiratory 
infection
0.77
(0.57 – 1.03)
0.74
(0.54 – 1.01)
1.25
(1.10 – 1.41)
1.25
(1.09 – 1.42)
1.28
(1.13 – 1.45)
1.29
(1.12 – 1.47)
1.04
(0.92 – 1.18)
1.05
(0.92 – 1.20)
Severe upper 
respiratory infection
1.21
(0.90 – 1.63)
1.14
(0.83 – 1.56)
1.24
(1.10 – 1.40)
1.23
(1.09 – 1.40)
1.18
(1.04 – 1.33)
1.18
(1.04 – 1.34)
1.04
(0.92 – 1.17)
1.05
(0.93 – 1.19)
Allergy
Any 0.98
(0.74 – 1.31)
1.00
(0.74 – 1.35)
1.30
(1.16 – 1.46)
1.26
(1.13 – 1.42)
1.20
(1.07 – 1.35)
1.18
(1.05 – 1.33)
1.12
(1 – 1.25)
1.11
(0.99 – 1.25)
Respiratory 1.14
(0.70 – 1.85)
1.13
(0.68 – 1.87)
1.24
(1.02 – 1.51)
1.20
(0.99 – 1.47)
1.10
(0.90 – 1.34)
1.09
(0.89 – 1.33)
1.05
(0.86 – 1.28)
1.05
(0.86 – 1.29)
1 Logistic regression analysis: adjusted for the core covariates including study area, age, gender, mother's education, and parental asthma.
2 Logistic regression analysis: adjusted for the core covariates, preterm delivery and low birth weight.Respiratory Research 2006, 7:48 http://respiratory-research.com/content/7/1/48
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